Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 17/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16009661 | 0.95 | PTGS2 (0.53) | PTGS2HTR1APKMPTGS1GLO1 | |
| SCHEMBL16024207 | 0.95 | PTGS2 (0.53) | PTGS2HTR1APKMPTGS1GLO1 | |
| SCHEMBL16017874 | 0.92 | PTGS2 (0.52) | PTGS2HTR1APKMPTGS1GLO1 | |
| Tobramycin SCHEMBL16011782 | 0.86 | PTGS2 (0.55) | PTGS2HTR1APKMPTGS1GLO1 | |
| SCHEMBL16010166 | 0.72 | PTGS2 (0.84) | PTGS2HTR1APKMPTGS1GLO1 | |
| SCHEMBL19376389 | 0.72 | PTGS2 (0.84) | PTGS2HTR1APKMPTGS1GLO1 | |
| SCHEMBL6754016 | 0.71 | PTGS2 (0.88) | PTGS2HTR1APKMPTGS1GLO1 | |
| SCHEMBL29170168 | 0.70 | PTGS2 (0.86) | PTGS2HTR1APKMPTGS1GLO1 | |
| SCHEMBL13813542 | 0.69 | PTGS2 (1.00) | PTGS2HTR1APKMPTGS1GLO1 | |
| SCHEMBL12742120 | 0.69 | PTGS2 (0.91) | PTGS2HTR1APKMPTGS1GLO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140256666-A1 | ANTIBIOTIC CONJUGATES WITH NONSTEROIDAL ANTI-INFLAMMATORY DRUGS | ALLERGAN, INC. (US) | 2014-09-11 | — | — | US | claimed |
| US-20140256666-A1 | ANTIBIOTIC CONJUGATES WITH NONSTEROIDAL ANTI-INFLAMMATORY DRUGS | ALLERGAN, INC. (US) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256666-A1 | ANTIBIOTIC CONJUGATES WITH NONSTEROIDAL ANTI-INFLAMMATORY DRUGS | MMP17, NAALAD2, DNPEP | PTGS2 76/4885HTR1A 3802/4885PKM 3450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.